Xanomeline

PureTech-invented KarXT receives FDA approval for schizophrenia treatment, triggering $29M in milestone payments and potential future royalties. KarXT, now marketed as Cobenfy by Bristol Myers Squibb, is the first new drug mechanism for schizophrenia in over 50 years.

PureTech Health announced FDA approval of KarXT for schizophrenia, triggering $29 million in milestone payments from Royalty Pharma and Karuna Therapeutics, acquired by Bristol Myers Squibb in 2024. KarXT will be marketed as Cobenfy, the first new drug mechanism for schizophrenia in over 50 years.

Bristol Myers Squibb's first-in-class treatment for schizophrenia, Cobenfy, approved by FDA, offers a new pharmacological approach. Clinical trials showed significant symptom reduction compared to placebo. Common adverse reactions include nausea, dyspepsia, and constipation. Cobenfy Cares™ support program launched for patients.

FDA approves Cobenfy, a first-in-class treatment for schizophrenia, offering a new pharmacological approach. Cobenfy, combining xanomeline and trospium chloride, demonstrated significant symptom reduction in trials, with common adverse reactions including nausea and hypertension. The approval marks a milestone in neuropsychiatry, providing a new option for managing schizophrenia.

FDA approves Cobenfy, a first-in-class treatment for schizophrenia, offering a new pharmacological approach. Cobenfy, combining xanomeline and trospium chloride, demonstrated significant symptom reduction in trials, with common adverse reactions including nausea and hypertension. The approval aims to transform schizophrenia treatment by leveraging a novel pathway in the brain.

FDA approves KarXT, a new schizophrenia treatment by Bristol Myers Squibb, offering improved symptoms and fewer side effects. KarXT, a combination of Xanomeline and trospium, targets muscarinic receptors and reduces digestive issues. The drug is expected to be cost-effective if priced between $16,000 and $20,000 per year, with 75% of patients seeing symptom improvement by 30% or more after one year.

FDA approves Cobenfy, first new schizophrenia drug in over 30 years, combining xanomeline and trospium chloride to manage symptoms via a different mechanism targeting acetylcholine, potentially reducing common side effects like weight gain and drowsiness.

The FDA approved xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia, marking the first new pharmacological approach since the 1970s. The drug, a dual M1/M4 muscarinic acetylcholine receptor agonist, offers a new treatment alternative without common adverse events like weight gain or movement disorders, based on phase 3 EMERGENT trials.

The FDA is set to share results on Bristol Myers Squibb’s KarXT for schizophrenia, which targets muscarinic receptors. KarXT, a combination of xanomeline and trospium, shows potential as a breakthrough treatment with a unique mechanism and fewer adverse effects. The approval could lead to further innovations in schizophrenia treatment, aiming for safer, more effective, and easier-to-use medications.